Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Clin Transl Oncol. 2011 Mar;13(3):209-10. doi: 10.1007/s12094-011-0642-9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab
  • Brain Neoplasms / drug therapy*
  • Drug Approval / legislation & jurisprudence*
  • Europe
  • Glioma / drug therapy*
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab